# OnCo record paper-transcend-nhl-001-liso-cel-lancet-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-transcend-nhl-001-liso-cel-lancet-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-transcend-nhl-001-liso-cel-lancet-2020" ;
  schema:name "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study"@en ;
  schema:alternateName "TRANSCEND NHL 001"@en, "Abramson 2020"@en, "JCAR017 pivotal study"@en ;
  schema:description "The pivotal study of the third CAR-T product for lymphoma, built from a fixed one-to-one mix of two kinds of T cell, with severe immune side effects in only a small minority."@en ;
  schema:url <https://onco.cc/key-papers/paper-transcend-nhl-001-liso-cel-lancet-2020/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(20)31366-0>, <https://pubmed.ncbi.nlm.nih.gov/32888407/>, <https://europepmc.org/article/MED/32888407> ;
  onco:tag "lymphoma-evidence" ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(20)31366-0> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Abramson JS, Palomba ML, Gordon LI, et al." ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:drugs <https://onco.cc/drugs/lisocabtagene-maraleucel/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/orr/>, <https://onco.cc/terms/complete-response/>, <https://onco.cc/terms/double-hit-lymphoma/> ;
  onco:trials <https://onco.cc/trials/transcend-nhl-001/>, <https://onco.cc/trials/transform/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-aging-comorbidity/> ;
  onco:journals <https://onco.cc/journals/lancet/> .